Overview

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Status:
RECRUITING

Trial end date:
2026-05-23

Target enrollment:

Participant gender:

Summary

A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma

Phase:

PHASE3

Details

Lead Sponsor:

Akeso

Treatments:

lenvatinib